Healthcare
Live Price
Offline$0.0042
+31.25% today
1Y Change
-74.23%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regen BioPharma, Inc. (RGBPP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 74.2% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +0.0%, EPS growth of +76.2%, a dividend yield of 0.0%. What stands out right now is revenue +0.0%, EPS +76.2%, free cash flow +49.0% with operating margin -350.3% and ROIC 15.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines RGBPP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGBPP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGBPP Max Drawdown
-98.11%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGBPP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$171.2K
-27.3% YoY
FY Net Income
-$7.1M
-231.2% YoY
Free Cash Flow
-$1.1M
-86.3% YoY
Revenue Growth
+0.0%
EPS Growth
+76.2%
Gross Margin
100.0%
Net Margin
-730.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 237K | 237K | 237K | 236K | 171K |
| Gross Profit | 237K | 237K | 237K | 186K | 146K |
| Operating Income | -339K | -418K | -687K | -340K | -201K |
| EBITDA | -339K | -417K | 3M | 3M | -6M |
| Net Income | -1M | -668K | 1M | 5M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 716 | 716 | 121K | 51K | 727K |
| Total Assets | 275K | 161K | 354K | 559K | 1M |
| Total Liabilities | 7M | 5M | 5M | 9M | 15M |
| Shareholder Equity | -6M | -5M | -5M | -8M | -13M |
| Total Debt | 794K | 794K | 756K | 1M | 4M |
| Net Debt | 793K | 793K | 635K | 1M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-86.3% YoY
Capital Expenditures
0
Free Cash Flow
1M
-86.3% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-350.3%
Net Margin
-730.0%
ROE
28.3%
Debt / Equity
-0.18x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.